Table 2.
Composition of the stromal vascular fraction.
| HC patients (N = 3) | OI patients (N = 18) | P–value | |
|---|---|---|---|
| Viability |
80.5 ± 5.3% (71.8–90.2) |
85.0 ± 4.0% (44.3–97.6) |
0.31 |
| Early mesenchymal stem cells |
34.8 ± 2.8% (30.0–39.9) |
35.7 ± 5.2% (2.2–85.5) |
0.95 |
| Activated mesenchymal stem cells |
0 ± 0% (0–0) |
0.05 ± 0.03% (0–0.33) |
0.46 |
| Endothelial progenitors |
12.6 ± 4.9% (4.4–21.4) |
4.9 ± 1.4% (0.4–20.3) |
0.035 |
| Pericytes |
4.0 ± 1.7% (1.2–6.9) |
3.7 ± 1.4% (0.1–24.7) |
0.37 |
| Supra-adventitial stromal cells |
41.8 ± 5.0% (32.7–49.9) |
38.0 ± 5.5% (2.6–87.2) |
0.79 |
| Monocytes |
3.6 ± 2.2% (0.3–7.9) |
2.7 ± 0.8% (0.04–11.4) |
0.55 |
| Macrophages |
2.2 ± 0.3% (1.7–2.8) |
4.3 ± 1.0% (0.3–13.4) |
0.69 |
| Hematopoietic cells |
17.4 ± 2.5% (12.8–21.5) |
15.8 ± 1.8% (0.6–29.3) |
0.72 |
Data represent mean ± SEM (minimum—maximum). P values represent significance of the difference between HC and OI patients using Mann–Whitney-U-Test.